MEDI5752 for solid tumors with immune tissue structures
Part of Cancer clinical trials.
This trial tests MEDI5752, a drug designed to help the immune system attack solid tumors. It is aimed at people whose tumors have “mature tertiary lymphoid structures,” and it may be especially relevant if your cancer has not responded well enough to immune checkpoint drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed solid tumor shown by tissue testing (biopsy or surgery).
- You have advanced cancer that cannot be removed or has spread, and at least one measurable spot on scans.
- Your tumor has “mature tertiary lymphoid structures,” either already confirmed at the sponsor’s institute or confirmed by central review from a stored FFPE tissue sample.
- You are either immune therapy–naïve (no prior PD-1/PD-L1 treatment) or, if you had PD-1/PD-L1 treatment before, you must have initially benefited for at least 4 months without tumor growth during that time (then later progressed).
- You can have a research biopsy (a tumor sample) if needed, and you must be able to recover from prior treatment side effects to a mild level (grade 1 or less).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests T3P, a new treatment given directly into reachable solid tumors, to see if it is safe and can help shrink tumors. It is for adults with advanced cancers when no curative treatment is available.
This early-phase trial tests NB002, a new immune-targeting medicine, to find safe doses and see how well it can treat advanced or metastatic solid cancers that have not responded to standard treatments. It may help by strengthening the immune system’s ability to fight the tumor.
This study tests a new drug (DS5361b) for people with advanced solid tumors that have high genetic instability (TMB-H or MSI-H). It aims to see if the drug can shrink tumors or slow their growth.
This trial tests an experimental drug called IPN01203 for people with advanced solid tumors that have grown after prior immunotherapy. The goal is to see if the drug is safe and can shrink tumors.
This trial tests a new type of immune cell therapy (gamma-delta T cells that have been modified to target PD-1) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if these cells can help your immune system fight the cancer.
This trial tests a new drug, D3L-002, for people with advanced solid tumors that have stopped responding to at least one prior treatment or have no standard options. The goal is to see if it can help shrink or control the cancer.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.